Skip to content
OpenCapital
Get started

CONMED CNMD Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Stryker logo
StrykerSYK
$415M+227%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
Vericel logo
VericelVCEL
$15.13M+299%
OSI Systems logo
OSI SystemsOSIS
$6.9M-91.1%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
——

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%

Valuation

See full
Market cap$1.07B-34.0%
Enterprise value$1.89B-23.5%
P/E19.4×+5.8×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Calculated from CONMED’s reported figures.

$13.5Mnet cash from operating−$2.9Mcapital expenditures=$10.58M

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's free cash flow?
CONMED (CNMD) reported free cash flow of $10.58M in Q1 2026.
How has CONMED's free cash flow changed year-over-year?
CONMED's free cash flow decreased by 72.0% year-over-year, from $37.76M to $10.58M.
What is the long-term trend for CONMED's free cash flow?
Over 3 years (2021 to 2025), CONMED's free cash flow has grown at a 15.9% compound annual growth rate (CAGR), from $96.9M to $150.88M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.